Zai Lab Limited (ZLAB)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB). Investors who purchased Zai Lab shares are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Zai Lab and certain of its officers and/or directors have violated federal securities laws.
On March 9, 2022, the U.S. Securities and Exchange Commission (“SEC”) published a notification identifying Zai Lab, among other companies, as in potential violation of the Holding Foreign Companies Accountable Act, which allows the SEC to delist companies and ban a company’s shares from being traded if the company fails to allow U.S. regulators to review their company audits for three straight years. Zai Lab and the other companies named in the SEC notification have until March 29, 2022 to challenge the charges against them. On this news, Zai Lab’s stock price fell $6.74 per share, or 18.34%, to close at $30.02 per share on March 10, 2022.
If you are aware of any facts relating to this investigation, or purchased Zai Lab shares you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.